137 related articles for article (PubMed ID: 19641035)
1. The translesion polymerase Rev3L in the tolerance of alkylating anticancer drugs.
Roos WP; Tsaalbi-Shtylik A; Tsaryk R; Güvercin F; de Wind N; Kaina B
Mol Pharmacol; 2009 Oct; 76(4):927-34. PubMed ID: 19641035
[TBL] [Abstract][Full Text] [Related]
2. Xrcc2 deficiency sensitizes cells to apoptosis by MNNG and the alkylating anticancer drugs temozolomide, fotemustine and mafosfamide.
Tsaryk R; Fabian K; Thacker J; Kaina B
Cancer Lett; 2006 Aug; 239(2):305-13. PubMed ID: 16298473
[TBL] [Abstract][Full Text] [Related]
3. New cytotoxic agents for the treatment of metastatic malignant melanoma: temozolomide and related alkylating agents in combination with guanine analogues to abrogate drug resistance.
Spiro T; Liu L; Gerson S
Forum (Genova); 2000; 10(3):274-85. PubMed ID: 11007934
[TBL] [Abstract][Full Text] [Related]
4. Activity of fotemustine in medulloblastoma and malignant glioma xenografts in relation to O6-alkylguanine-DNA alkyltransferase and alkylpurine-DNA N-glycosylase activity.
Vassal G; Boland I; Terrier-Lacombe MJ; Watson AJ; Margison GP; Vénuat AM; Morizet J; Parker F; Lacroix C; Lellouch-Tubiana A; Pierre-Kahn A; Poullain MG; Gouyette A
Clin Cancer Res; 1998 Feb; 4(2):463-8. PubMed ID: 9516937
[TBL] [Abstract][Full Text] [Related]
5. Nijmegen breakage syndrome protein (NBN) causes resistance to methylating anticancer drugs such as temozolomide.
Eich M; Roos WP; Dianov GL; Digweed M; Kaina B
Mol Pharmacol; 2010 Nov; 78(5):943-51. PubMed ID: 20729302
[TBL] [Abstract][Full Text] [Related]
6. Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine.
Roos WP; Batista LF; Naumann SC; Wick W; Weller M; Menck CF; Kaina B
Oncogene; 2007 Jan; 26(2):186-97. PubMed ID: 16819506
[TBL] [Abstract][Full Text] [Related]
7. Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication.
Aghi M; Rabkin S; Martuza RL
J Natl Cancer Inst; 2006 Jan; 98(1):38-50. PubMed ID: 16391370
[TBL] [Abstract][Full Text] [Related]
8. Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to methylating agents.
Liu L; Taverna P; Whitacre CM; Chatterjee S; Gerson SL
Clin Cancer Res; 1999 Oct; 5(10):2908-17. PubMed ID: 10537360
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of O6-methylguanine-DNA methyltransferase by glucose-conjugated inhibitors: comparison with nonconjugated inhibitors and effect on fotemustine and temozolomide-induced cell death.
Kaina B; Mühlhausen U; Piee-Staffa A; Christmann M; Garcia Boy R; Rösch F; Schirrmacher R
J Pharmacol Exp Ther; 2004 Nov; 311(2):585-93. PubMed ID: 15254145
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxicity, DNA damage, and apoptosis induced by new fotemustine analogs on human melanoma cells in relation to O6-methylguanine DNA-methyltransferase expression.
Passagne I; Evrard A; Winum JY; Depeille P; Cuq P; Montero JL; Cupissol D; Vian L
J Pharmacol Exp Ther; 2003 Nov; 307(2):816-23. PubMed ID: 12970393
[TBL] [Abstract][Full Text] [Related]
11. c-Myc-miR-29c-REV3L signalling pathway drives the acquisition of temozolomide resistance in glioblastoma.
Luo H; Chen Z; Wang S; Zhang R; Qiu W; Zhao L; Peng C; Xu R; Chen W; Wang HW; Chen Y; Yang J; Zhang X; Zhang S; Chen D; Wu W; Zhao C; Cheng G; Jiang T; Lu D; You Y; Liu N; Wang H
Brain; 2015 Dec; 138(Pt 12):3654-72. PubMed ID: 26450587
[TBL] [Abstract][Full Text] [Related]
12. Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications.
Zhang J; Stevens MF; Laughton CA; Madhusudan S; Bradshaw TD
Oncology; 2010; 78(2):103-14. PubMed ID: 20357518
[TBL] [Abstract][Full Text] [Related]
13. Role of wild-type p53 on the antineoplastic activity of temozolomide alone or combined with inhibitors of poly(ADP-ribose) polymerase.
Tentori L; Lacal PM; Benincasa E; Franco D; Faraoni I; Bonmassar E; Graziani G
J Pharmacol Exp Ther; 1998 May; 285(2):884-93. PubMed ID: 9580640
[TBL] [Abstract][Full Text] [Related]
14. Influence of O6-methylguanine on DNA damage and cytotoxicity of temozolomide in L1210 mouse leukemia sensitive and resistant to chloroethylnitrosoureas.
Taverna P; Catapano CV; Citti L; Bonfanti M; D'Incalci M
Anticancer Drugs; 1992 Aug; 3(4):401-5. PubMed ID: 1421437
[TBL] [Abstract][Full Text] [Related]
15. Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea.
Liu L; Markowitz S; Gerson SL
Cancer Res; 1996 Dec; 56(23):5375-9. PubMed ID: 8968088
[TBL] [Abstract][Full Text] [Related]
16. Triazene compounds: mechanism of action and related DNA repair systems.
Marchesi F; Turriziani M; Tortorelli G; Avvisati G; Torino F; De Vecchis L
Pharmacol Res; 2007 Oct; 56(4):275-87. PubMed ID: 17897837
[TBL] [Abstract][Full Text] [Related]
17. O6-methylguanine-DNA methyltransferase, O6-benzylguanine, and resistance to clinical alkylators in pediatric primary brain tumor cell lines.
Bobola MS; Silber JR; Ellenbogen RG; Geyer JR; Blank A; Goff RD
Clin Cancer Res; 2005 Apr; 11(7):2747-55. PubMed ID: 15814657
[TBL] [Abstract][Full Text] [Related]
18. O6-methylguanine and temozolomide can reverse the resistance to chloroethylnitrosoureas of a mouse L1210 leukemia.
D'Incalci M; Taverna P; Erba E; Filippeschi S; Potenza D; Mariani L; Citti L; Catapano CV
Anticancer Res; 1991; 11(1):115-21. PubMed ID: 2018345
[TBL] [Abstract][Full Text] [Related]
19. The role of base excision repair in the sensitivity and resistance to temozolomide-mediated cell death.
Trivedi RN; Almeida KH; Fornsaglio JL; Schamus S; Sobol RW
Cancer Res; 2005 Jul; 65(14):6394-400. PubMed ID: 16024643
[TBL] [Abstract][Full Text] [Related]
20. DNA repair in personalized brain cancer therapy with temozolomide and nitrosoureas.
Kaina B; Christmann M
DNA Repair (Amst); 2019 Jun; 78():128-141. PubMed ID: 31039537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
